Marketing-authorisation holder
Otsuka
16 medicines in 1 country, as authorisation holder.
Loading…
Marketing-authorisation holder
16 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
16 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABILIFY1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Aripiprazole | United States | Not marketed | 2004 |
| ABILIFY10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 30MG **Federal Register d · Tablet, orally disintegrating | Aripiprazole | United States | Not marketed | 2006 |
| ABILIFY10mg | 15mg | 20mg | 2mg | 30mg | 5mg · Tablet | Aripiprazole | United States | Marketed | 2002 |
| ABILIFY9.75mg/1.3ml (7.5mg/ml) · Injectable | Aripiprazole | United States | Not marketed | 2006 |
| ABILIFY ASIMTUFII720mg/2.4ml (300mg/ml) | 960mg/3.2ml (300mg/ml) · Suspension, extended release | Aripiprazole | United States | Marketed | 2023 |
| ABILIFY MAINTENA KIT300mg | 300mg/vial | 400mg | 400mg/vial · For suspension, extended release | Aripiprazole | United States | Marketed | 2013 |
| ABILIFY MYCITE KIT10mg | 15mg | 20mg | 2mg | 30mg | 5mg · Tablet | Aripiprazole | United States | Not marketed | 2017 |
| BUSULFEX6mg/ml · Injectable | Busulfan | United States | Marketed | 1999 |
| DACOGEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Decitabine | United States | Not marketed | 2006 |
| FERRISELTZ600mg/packet · For solution | Ferric ammonium | United States | Not marketed | 1997 |
| JYNARQUE15mg | 30mg | 45mg | 60mg | 90mg · Tablet | Tolvaptan | United States | Marketed | 2018 |
| PLETAL100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Cilostazol | United States | Not marketed | 1999 |
| RAXAR200mg base | 400mg base | 600mg base · Tablet | Grepafloxacin | United States | Not marketed | 1997 |
| REXULTI0.25mg | 0.5mg | 1mg | 2mg | 3mg | 4mg · Tablet | Brexpiprazole | United States | Marketed | 2015 |
| SAMSCA15MG | 30MG | 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Tolvaptan | United States | Marketed | 2009 |
| VOYXACT400mg/2ml(200mg/ml) · Injectable | Sibeprenlimab | United States | Marketed | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 16 | 16 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Keep Otsuka’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.